In this retrospective study we evaluated the efficacy and feasibility of the 2-week regimen of TS-1 with a one-week drug-free interval after each two-week dosing session in comparison with the conventional 4-week regimen as the historical control. The subjects were 27 patients (13 patients of the 2-week regimen and 14 of 4-week regimen) with advanced or recurrent gastric cancer who received TS-1 therapy. The incidence of adverse reactions tended to be lower in the 2-week regimen group (77%) than in the 4-week regimen group (93%). There was no significant difference between the response rate and the median survival time of the 2-week regimen and that of the 4-week regimen.
展开▼
